LoginSignup
Valneva logo

Valneva

Stock
Stock
ISIN: FR0004056851
Ticker: VLA
FR0004056851
VLA

Price

Price

CHART BY

Frequently asked questions

The market capitalization of Valneva is $612.23M. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
Valneva's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$1.021. EPS indicates the company's profitability on a per-share basis.
Currently, 10 analysts cover Valneva's stock, with a consensus target price of $6.257. Analyst ratings provide insights into the stock's expected performance.
Over the trailing twelve months, Valneva reported a revenue of $162.60M.
Valneva's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$117.05M. EBITDA measures the company's overall financial performance.
Valneva has a free cash flow of -$99.28M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
Valneva employs approximately 674 people. It operates in the Health Care sector, specifically within the Biotechnology industry.
The free float of Valneva is 170.11M. Free float refers to the number of shares available for public trading, excluding restricted shares.

Financials

Market Cap 
$612.23M
EPS (TTM) 
-$1.021
Free Float 
170.11M
Revenue (TTM) 
$162.60M
EBITDA (TTM) 
-$117.05M
Free Cashflow (TTM) 
-$99.28M

Pricing

1D span
$3.064$3.225
52W span
$2.313$6.26

Analyst Ratings

The price target is $6.257 and the stock is covered by 10 analysts.

Buy

9

Hold

0

Sell

1

Information

Valneva SE is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. It currently provides three proprietary travel vaccines: IXIARO, DUKORAL, and IXCHIQ. The IXIARO is an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis in adults, adolescents, children, and infants aged two months and older. The DUKORAL is a drinkable vaccine that helps prevent diarrhea caused by heat-labile toxin-producing ETEC, as well as cholera. The IXCHIQ is a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus. The company also offers additional vaccines, including VLA1553, VLA15, VLA160, VLA200, VLA1601 and others. Valneva was founded on May 28, 2013 and is headquartered in Saint-Herblain, France.

Employees
674
Industries
Biotechnology
Sector
Health Care

Identifier

ISIN
FR0004056851
Primary Ticker
VLA

Knockouts

Real-time data from LSX · Fundamentals & EOD data from FactSet
Join the conversation
Sign upLogin